Acumen Pharmaceuticals, Inc., was incorporated in Delaware in 1996. The company is a clinical-stage biopharmaceutical company that is developing a new disease-modifying approach to target what the company believes is a key root cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that causes loss of memory and cognitive function, and ultimately death.
